Stephen Tomlinson to Molecular Targeted Therapy
This is a "connection" page, showing publications Stephen Tomlinson has written about Molecular Targeted Therapy.
Connection Strength
0.851
-
Tissue-targeted complement therapeutics. Mol Immunol. 2018 10; 102:120-128.
Score: 0.555
-
Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis. Clin Exp Immunol. 2015 Mar; 179(3):500-8.
Score: 0.110
-
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
Score: 0.090
-
In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
Score: 0.043
-
New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7.
Score: 0.030
-
Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. Neurosci Lett. 2012 Nov 30; 531(1):35-9.
Score: 0.023